[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dialysis-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dialysis-complications":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,43,74,101,125,159,185,208,228,252,275,304,325,346,374,399,423],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100526980","twice-vs-thrice-weekly-incident-hemodialysis-in-elderly-patients-100526980",false,"NCT06141798","Twice vs Thrice Weekly Incident Hemodialysis in Elderly Patients","A Pragmatic Randomized Clinical Trial: Twice-weekly vs Thrice-weekly Incident hemoDialysis in Elderly Patients","Inclusion Criteria:\n\n* Age ≥60 years\n* Clinical diagnosis of end stage kidney disease\n* Starting maintenance hemodialysis within one month\n* 24-hour urine output ≥ 500 ml at randomization\n* Sufficient understanding of the study procedures and requirements.\n\nExclusion Criteria:\n\n* Left ventricular ejection fraction \\\u003C 40%)\n* Liver cirrhosis\n* Current treatment for an active malignancy or active infection\n* Onability or refusal to provide written informed consent\n* enrollment in another clinical trial.","ALL","60 Years",{"count":19,"type":20},428,"ESTIMATED","INTERVENTIONAL",[23],"NA","As Korea is becoming a super-aged society, the number of elderly patients with end-stage kidney disease (ESKD) is expected to increase rapidly. Therefore, the burden on Korean society will also increase.\n\nThrice-weekly hemodialysis is standard for renal replacement therapy. However, this regimen has not been validated for elderly ESKD patients with residual renal function. Elderly patients can have multiple comorbidities such as hypertension, diabetes, cardiovascular disease, and impaired physical activity. Frequent hemodialysis could provoke falls, hypotension, and cognitive impairment. Previous reports have suggested the potential benefit of twice-weekly hemodialysis with incremental increases in frequency when residual renal function decreases. In addition, twice-weekly hemodialysis decreases hospitalization rates in frail patients.\n\nTherefore, the investigators hypothesized initiating renal replacement therapy with twice-weekly hemodialysis decreases the hopsitalizatoin rates compared with conventional thrice-weekly hemodialysis in elderly ESRD patients with residual renal function. This study is a pragmatic randomized clinical trial, multicenter study. Study subjects are incident ESRD patients (\\>= 60 years old, n=428) with residual urine volume ( \\> 500 mL\u002Fday) and follow up up to 2 years. Twice-weekly hemodialysis could be incremented according to clinical situations such as volume overload, hyperkalemia and uremic symptom. Primary outcome of this study is hospitalization rate during follow-up. Secondary outcomes include dialysis related hospitalization rate, the length of hospital stay, complication of dialysis,mortality rate and assessments of quality of life, frailty, and cost-utility.",[26,27,28,29],"Age Problem","Dialysis; Complications","Frailty","Quality of Life","RECRUITING","2026-05-06",{"date":33,"type":34},"2026-05-11","ACTUAL",{"date":36,"type":34},"2021-11-23",{"date":38,"type":20},"2026-05-31",{"name":40,"class":41},"Soonchunhyang University Hospital","OTHER",7,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100550412","low-dose-intensity-vs-standard-dose-intensity-continuous-renal-replacement-therapy-in-critically-ill-patients-wisdom-100550412","NCT06446739","LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM)","LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM): A Pilot Randomized Trial","WISDOM","Inclusion Criteria:\n\n* age ≥ 18 years\n* weight ≥ 55 kg\n* plan to initiate CRRT or within 24 hours of having started CRRT for AKI\n* expected to survive and receive CRRT for a duration of ≥ 48 hours\n* able to provide informed consent or have an authorized representative provide consent after being informed on the details and risks of the trial unless a deferred consent process is approved by local Research Ethics Board (REB).\n\nExclusion Criteria:\n\n* indication for sustained higher dose-intensity CRRT as designated by the attending clinicians\n* end-stage kidney disease receiving maintenance dialysis\n* receipt of any RRT for AKI during the current hospitalization\n* inability to comply with the requirements of the study protocol.","18 Years",{"count":53,"type":20},100,[23],"An estimated 10-15% of critically ill patients with acute kidney failure in the intensive care unit receive acute dialysis therapy. The majority of these patients initially receive a continuous form of dialysis therapy call continuous renal replacement therapy (CRRT). Prior studies have suggested that higher CRRT dose-intensity improved health outcomes for these patients; however, this was not found in high-quality clinical trials. These more recent trials suggested a lower range of dose-intensity compared with the higher range as the new standard of care. This was incorporated into guidelines. To date, no clinical trials have evaluated this lower range and specifically, it is plausible that an even lower dose-intensity of CRRT may be well tolerated, safe, associated with similar outcomes and be more cost-effective. This is the objective of the WISDOM trial, to compare the guideline standard with lower dose-intensity among patients who are started on CRRT in the intensive care unit.",[57,27],"Acute Kidney Injury",[59,60,61,62,63],"acute kidney injury","continuous renal replacement therapy","dose-intensity","randomized trial","pilot feasibility","2026-04-24",{"date":66,"type":34},"2026-04-28",{"date":68,"type":34},"2024-11-14",{"date":70,"type":20},"2027-06",{"name":72,"class":41},"University of Alberta",9,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100627373","wisdom-uk-low-dose-intensity-versus-standard-dose-intensity-crrt-in-critically-ill-patients-100627373","NCT07447791","WISDOM UK: Low Dose-intensity Versus Standard Dose-intensity CRRT in Critically Ill Patients","WISDOM UK: Low Dose-intensity Versus Standard Dose-intensity Continuous Renal Replacement Therapy in Critically Ill Patients: a Randomized Trial","WISDOM UK","Inclusion Criteria:\n\n* age ≥ 18 years\n* patient weight ≥ 55 kg\n* plan to start CRRT or within 24 hours of having started CRRT for AKI\n* expected to survive and receive CRRT for a duration of ≥ 48 hours\n\nExclusion Criteria:\n\n* indication for sustained higher dose-intensity CRRT\n* end-stage kidney disease receiving maintenance dialysis\n* previous receipt of RRT for AKI during the current hospitalization\n* inability to comply with the requirements of the study protocol",{"count":83,"type":20},20,[23],"Acute kidney injury is a potentially life threatening condition which affects 1 in 2 patients in the Intensive Care Unit (ICU). Patients often need dialysis treatment, also called renal replacement therapy. Renal replacement therapy is a treatment that removes toxins and excess fluid from the blood stream. It consists of having a small plastic catheter in a vein in the neck or in the groin through which blood flows through a dialysis machine and is cleansed and excess water is removed. The cleansed blood is then returned to the patient via the same catheter.\n\nOne of the major areas of uncertainty for doctors in the ICU is \"What is the right intensity of renal replacement therapy for patients with acute kidney injury?\" A higher intensity indeed removes more toxins but also removes other substances in the blood, including vitamins, nutrients and important medications. The current usual dose is around 25 ml\u002Fkg\u002Fhr but clinical practice in the UK is very variable and some patients routinely receive higher doses and some get lower doses. Data from large databases worldwide have suggested that a lower dose is safe and effective and may potentially allow the kidneys to recover faster but confirmation is lacking.\n\nIn this study, the investigators investigate whether renal replacement therapy at a lower intensity is as effective and safe as currently used doses. Participants will be randomised to receiving renal replacement therapy at usual or lower intensity. There will be no change to any other aspects of treatment.\n\nThe results will inform the investigators whether the study protocol is feasible and how best to design a future larger research study.",[87,27],"Acute Kidney Injury (Nontraumatic)",[89,90,59],"renal replacement therapy","dose","2026-03-03",{"date":93,"type":34},"2026-03-05",{"date":95,"type":34},"2025-02-15",{"date":97,"type":20},"2027-03-30",{"name":99,"class":41},"Guy's and St Thomas' NHS Foundation Trust",1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":124},"100476920","access-cannulation-trial-ii-100476920","NCT05490225","Access Cannulation Trial II","A Study to Evaluate the Safety and Effectiveness of Voyager's Access Device for Patients Undergoing Routine Hemodialysis (Access Cannulation Trial II)","ACT II","Inclusion:\n\n1. The subject's AVF is deemed uncannulatable because:\n\n   1. The subject's anticipated cannulation zone(s) is\u002Fare \\>6mm in depth from the surface of the skin to the anterior wall of the access vein as confirmed by ultrasound within 8 weeks prior to device implantation (each zone, Arterial\u002FPull and Venous\u002FPush, shall be assessed independently of one another for device placement):\n\n      * Arterial\u002FPull Zone: \\_\\_\\_\\_\\_ mm deep\n      * Venous\u002FPush Zone: \\_\\_\\_\\_\\_ mm deep\n\n      OR\n   2. The subject's dialysis unit (which includes an experienced cannulator) attests that repeated cannulation is not achievable in their clinic due to one of the following:\n\n      * Failed access attempt in a fistula that was previously approved for cannulation, or\n      * Unable to palpate the fistula such that cannulation is not possible without patient risk.\n2. The access surgeon caring for the subject attests that the device is likely to be at least equivalent to other methods (such as venous transposition or suction-assisted lipectomy) that could make the AVF easier to access and reduce risk of cannulation infiltrations.\n3. The subject has either a radio-cephalic, brachio-cephalic or transposed brachio-basilic fistula.\n\nExclusion:\n\n1. The subject's access vein is \\>15mm in depth at either cannulation zones as measured by ultrasound within 8 weeks prior to device implantation.\n\n   * Arterial\u002FPull Zone: \\_\\_\\_\\_\\_ mm in depth\n   * Venous\u002FPush Zone: \\_\\_\\_\\_\\_ mm in depth Note: these values should match inclusion criteria #1\n2. Both bidimensional measurements in the subject's access vein have a diameter of \\\u003C4mm, taken with a tourniquet in place or through manual compression to the outflow, as measured by ultrasound within 8 weeks prior to device implantation (cannulation zone specific - one zone does not affect the other's eligibility).\n\n   * Arterial\u002FPull Zone: \\_\\_\\_\\_\\_ x \\_\\_\\_\\_\\_ mm in diameter\n   * Venous\u002FPush Zone: \\_\\_\\_\\_\\_ x \\_\\_\\_\\_\\_ mm in diameter\n3. The subject has a flow rate of \\\u003C550mL\u002Fmin in the inflow artery proximal to the arterial anastomosis as measured by ultrasound within 8 weeks prior to device implantation.\n\n   • Flow: \\_\\_\\_\\_\\_ mL\u002Fmin\n4. The subject does NOT have a prescription to receive maintenance hemodialysis at least 2 times per week.\n5. The subject's life expectancy is \\\u003C1 year per the Investigator.\n6. The subject does NOT have a signed and dated consent form.\n7. The AVF is a non-transposed basilic or brachial vein outflow AVF.\n8. The subject has high flow rates placing them at risk for heart failure and death at the discretion of the Investigator.\n9. The subject has a known skin infection, hypersensitive skin, skin breakdown\u002Ferosion or skin allergies at the potential implant sites.\n10. The subject has a known active systemic infection or positive blood cultures present.\n11. The subject's AVF has undergone a major revision and at the discretion of the Investigator can impact fistula viability and device placement (such as DRIL or PTFE segment insertion, banding, aneurysm repair, etc.), or the subject has had an occurrence of and\u002For intervention for AV access stenosis or thrombosis within the past month (excluded to avoid unnecessary placement into an AVF with a high likelihood of failure).\n12. The subject is \\\u003C18 years of age.\n13. The subject plans to become pregnant prior to their potential treatment date.\n14. The subject has a body mass index \\>50kg\u002Fm2.\n15. The subject has a known clinically significant bleeding or coagulation disorder, including but not limited to low platelet count (\\\u003C50,000), hypercoagulable state (e.g., antithrombin IE deficiency, antiphospholipid or anticardiolipin antibodies, Factor V Leiden, circulating Lupus anticoagulant, current, heparin-induced thrombocytopenia, protein C or S deficiency, history of recurrent deep vein thrombosis not related to AV access).\n16. The subject has an active malignancy.\n17. The subject has a known or suspected allergy to titanium, aluminum, or vanadium.\n18. The subject has had a significant cardiovascular event\u002Fintervention that makes them a poor surgical candidate such as myocardial infarction, angioplasty, or stent placement within 3 months of implantation.\n19. The subject has had a significant peripheral vascular disease requiring a major intervention within the previous 12 months (in the target limb).\n20. The subject has had a significant neurovascular event such as stroke or major intervention within the previous 12 months.\n21. The subject has an uncontrolled major symptomatic medical problem per the Investigator.\n22. The subject has a likelihood of poor protocol compliance due to mental incapacity, an inability to understand treatment instructions, or for any other reason in the opinion of the Investigator.\n23. The subject is currently participating in another investigational drug or device investigation that could clinically interfere with the endpoints of this investigation.\n24. The subject's conversion to home hemodialysis is anticipated at any point during their foreseeable participation in this investigation.",{"count":53,"type":20},[23],"This is a pivotal, interventional, prospective, single-arm, open-label, multi-site clinical investigation intended to support FDA clearance of the study device based on the safety and efficacy of the device in cannulating arteriovenous fistulas (AVFs) for hemodialysis procedures.",[27,113],"Vascular Access Complication","2025-10-27",{"date":116,"type":34},"2025-10-29",{"date":118,"type":34},"2025-04-23",{"date":120,"type":20},"2027-03-25",{"name":122,"class":123},"Voyager Biomedical","INDUSTRY",8,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":138,"conditions":139,"keywords":144,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":100},"100596415","phase-4-pegmolesatide-treatment-for-anemia-in-patients-undergoing-long-term-dialysis-100596415","NCT07045155","Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis","Pegmolesatide for Anemia Treatment：Investigation Upgrade Therapy in rhuEPO Patients Undergoing Dialysis: A Prospective, Multicenter, Parallel-Group, Controlled, Open-Label Study（PANGU-stepup）","PANGU-stepup","Inclusion Criteria:\n\n1. Aged ≥18 years and ≤80 years, with no restrictions on gender.\n2. Body weight ≥40 kg and body mass index (BMI) ≥18 kg\u002Fm².\n3. Subjects who have received hemodialysis or peritoneal dialysis for ≥3 months prior to enrollment;\n4. Subjects who have been receiving erythropoiesis-stimulating agents (ESAs) for ≥4 weeks prior to randomization, with an average weekly dose \\>6000 IU in the last 4 weeks (equivalent dose converted to short-acting EPO \\>6000 IU, calculated as the total amount of short-acting EPO used in the last 4 weeks divided by 4);\n5. The most recent Hb value during the screening period and the average Hb value between screening and baseline visits must be ≥70 to \\\u003C110 g\u002FL;\n6. Hemodialysis patients with serum ferritin levels ≥200 μg\u002FL; peritoneal dialysis patients with serum ferritin levels ≥100 μg\u002FL, and the investigator determines that renal transplant is not required during the trial;\n7. Understanding the study procedures and voluntarily signing the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n1. Known to have active malignancy, polycystic kidney disease, hematologic disorders (including congenital and acquired anemias such as thalassemia, Fanconi anemia, pure red cell aplasia, myelodysplastic syndromes, hemolytic anemia, and coagulation disorders), or other causes of anemia (such as gastrointestinal bleeding or hookworm disease);\n2. Known to have experienced stroke, transient ischemic attack, myocardial infarction, thromboembolic events (deep vein thrombosis), pulmonary embolism, or other serious cardiopulmonary diseases within the past 6 months;\n3. Received anabolic steroid (e.g., androgen) therapy within 12 weeks prior to randomization;\n4. Known to have received red blood cell or whole blood transfusion within 12 weeks prior to the study.\n5. History of significant infection within 4 weeks before randomization as determined by the investigator.\n6. Confirmed blood pressure measurements at rest and in a conscious state using standard measurement methods, with at least three non-consecutive day readings reaching or exceeding systolic blood pressure (SBP) ≥180 mmHg and\u002For diastolic blood pressure (DBP) ≥110 mmHg within 4 weeks before enrollment, or changes in antihypertensive medication treatment. The primary basis for judgment is clinic-measured blood pressure values, but \"white coat hypertension\" should be excluded.\n7. Known allergy to iron agents or polyethylene glycol.\n8. Pregnant or breastfeeding women, women of childbearing age with a positive blood β-HCG test result before the trial, or those planning to become pregnant during the study period.\n9. Scheduled for elective surgery during the trial period.\n10. Presence of any other factors that the investigator deems unsuitable for participation in this trial.","80 Years",{"count":135,"type":20},240,[137],"PHASE4","This study is a prospective, multicenter, parallel-controlled, open-label clinical trial, planned to be conducted across multiple research centers in various provinces and cities in China.\n\nIt will enroll 240 dialysis-dependent chronic kidney disease (DD-CKD) patients with anemia who have been receiving rHuEPO treatment for at least 4 weeks, with hemoglobin (Hb) levels of ≥70 g\u002FL and \\\u003C110 g\u002FL. After enrollment, participants will be randomly assigned in a 1:1:1 ratio to the experimental group, control group, and exploratory group. The study will involve a 24-week treatment and observation period, divided into three phases: a screening period (Day -28 to Day -1), a treatment period (Week 0 to Week 16), and an extension period (Week 17 to Week 24).\n\nThe primary objective is to assess the impact of the three treatment regimens on the hemoglobin levels of patients with DD-CKD anemia.",[27,140,141,142,143],"Chronic Kidney Disease 5D","Renal Anemia of Chronic Kidney Disease","Renal Anaemia","Renal Anemia, Chronic",[145,146,147,148,149],"recombinant human erythropoietin","erythropoietin mimetic peptides","Pegmolesatide","Dialysis","renal anemia","2025-09-08",{"date":152,"type":34},"2025-09-12",{"date":154,"type":34},"2025-08-01",{"date":156,"type":20},"2028-12-30",{"name":158,"class":41},"Chinese PLA General Hospital",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":167,"targetDuration":169,"studyType":170,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":100},"100334101","timing-of-renal-replacement-therapy-in-the-critically-ill-patients-100334101","NCT03629977","Timing of Renal Replacement Therapy in the Critically Ill Patients","Early vs Late CRRT, a Propensity Matched Multicenter Cohort Study","TORRT","Inclusion Criteria:\n\n\\*Critically ill patients admitted to intensive care units in Stockholm at: Karolinska University Hospital (Solna and Huddinge) and at Södersjukhuset.\n\n\\*Patients over 18 years of age\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years\n* Patients with DNAR (do not attempt resuscitation)-orders\n* Patients dying within 12 hours of commencing renal replacement therapy.",{"count":168,"type":20},50000,"1 Year","OBSERVATIONAL","Background: Severe acute kidney injury (AKI) among critically ill patients is sometimes treated with renal replacement therapy (RRT), and in Sweden continuous RRT (CRRT) is the dominant modality used in this population.\n\n* The optimal timing of renal replacement therapy (RRT) initiation in critically ill patients with acute kidney injury (AKI) is unknown\n* No consensus to guide clinical practice on this issue\n* Lack of consistency regarding outcome measurements; should we look at morbidity or mortality?\n* Wide variability in the timing of RRT initiation in the intensive care unit (ICU) population\n\nHypothesis: This is an important knowledge gap in the support of critically ill patients with AKI and we hypothesize that early initiation of RRT is beneficial.\n\nMethods: The present study aims to test this hypothesis by using a large scale high resolution intensive care database, the Clinisoft repository. In this database, we have information on \\>60 000 patients from three different hospitals and five ICUs, during the years 2005 up until today. The repository will be crossmatched, using the unique Swedish national ID number, with hospital records; to gather information on preexisting illnesses, chronic medication and post-ICU outcomes. It is likely that over 5%, more than 3000 patients, have been treated with RRT. We will categorize these patients into \"early\" and \"late\" groups using both biomarker data and clinical data. Importantly, early and late RRT can be categorized using biomarkers, like urea and creatinine; using degree of fluid accumulation, by level of pH in blood and just by using hours-days after ICU admission. All possible definitions of early\u002Flate RRT initiation can be tested in this study.\n\nOutcomes: Our primary outcome is 90 day mortality. Secondary outcomes include: mortality at 30, 60, 180 and 365 days. Two- and three year mortality.\n\nMorbidity, measured as end-stage renal disease (ESRD) for 90-day survivors. ICU length of stay, hospital length of stay.",[57,173,174,27,175],"Uremia","Fluid Overload","Critical Illness","2025-08-26",{"date":178,"type":34},"2025-09-03",{"date":180,"type":20},"2025-11-01",{"date":182,"type":20},"2027-04-01",{"name":184,"class":41},"Karolinska University Hospital",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":21,"phases":194,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":100},"100544872","evaluate-the-impact-of-targeted-physical-activity-on-clinically-debilitated-dialysis-patients-100544872","NCT06374537","Evaluate the Impact of Targeted Physical Activity on Clinically Debilitated Dialysis Patients.","Evaluating the Impact of Targeted Physical Activity on Clinically Debilitated Dialysis Patients.","Inclusion Criteria:\n\n* Clinically debilitated patients, currently on dialysis, or have CKD 4 (GFR between 15 and 29), or have CKD 5 (GFR below 15), or post- kidney transplant (for PPKT Subgroup only) as stated by patient's health care professional.\n* Adequate cognitive ability to complete the questionnaires, give consent for the study and follow the physical and diet instructions\n\nExclusion Criteria:\n\n* cardiac\u002Fpulmonary disease that contraindicate the physical training\n* Unable to give consent\n* Unable to travel to the training center",{"count":193,"type":20},150,[23],"This research is being done to better understand the impact of the use of a specific physical activity training program (GH Method) in dialysis\u002Fkidney disease patients.",[28,197,27,198],"Pain, Chronic","Kidney Diseases","2025-08-12",{"date":201,"type":34},"2025-08-14",{"date":203,"type":34},"2019-05-22",{"date":205,"type":20},"2027-05",{"name":207,"class":41},"University of Illinois at Chicago",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":214,"sex":16,"minAge":215,"maxAge":133,"enrollmentInfo":216,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":100},"100594652","assessment-of-thyroid-dysfunction-in-patients-undergoing-haemodialysis-at-sohag-university-hospital-100594652","NCT07022236","Assessment of Thyroid Dysfunction in Patients Undergoing Haemodialysis at Sohag University Hospital","Inclusion Criteria:\n\n* Adults aged 18 years and older.\n* Patients diagnosed with end-stage renal disease (ESRD) on regular hemodialysis for at least 3 months.\n\nExclusion Criteria:\n\n* Known Thyroid Disorders: Patients with a history of thyroid disease (e.g., hypothyroidism, hyperthyroidism) prior to starting dialysis.\n* Recent Thyroid Treatment: Patients who have received treatment for thyroid dysfunction (e.g., thyroid hormone replacement, antithyroid medications) within the last six months.\n* Patients with acute kidney injury (AKI) or those who are not on regular dialysis.\n* Pregnant or lactating women.\n* Patients with systemic illnesses or medications that could interfere with thyroid function tests (e.g., corticosteroids, lithium).",true,"13 Years",{"count":100,"type":20},"Thyroid dysfunction is a prevalent endocrine disorder that significantly impacts the health of patients with chronic kidney disease (CKD), particularly those undergoing dialysis. The prevalence of thyroid dysfunction in dialysis patients has been reported to range from 20% to 60%, highlighting the need for routine screening and management in this vulnerable group (Kuo et al., 2024). Thyroid hormones play a crucial role in regulating various physiological processes, and their dysregulation can lead to complications such as cardiovascular disease, anemia, and impaired quality of life, which are particularly concerning in the dialysis population (Smith et al., 2024).\n\nThe relationship between CKD and thyroid dysfunction is complex and multifactorial. Uremic toxins can interfere with the hypothalamic-pituitary-thyroid axis, leading to alterations in thyroid hormone production and metabolism. Recent studies have shown that inflammation and oxidative stress associated with CKD can further exacerbate thyroid dysfunction (Johnson et al., 2024). Understanding these mechanisms is essential for developing effective management strategies for thyroid health in dialysis patients.",[27],"2025-06-13",{"date":221,"type":34},"2025-06-15",{"date":223,"type":34},"2025-04-13",{"date":225,"type":20},"2025-10-30",{"name":227,"class":41},"Sohag University",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":21,"phases":237,"briefSummary":238,"conditions":239,"keywords":240,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":251},"100471420","effect-of-low-versus-high-dialysate-sodium-concentration-during-hemodialysis-on-dialysis-recovery-time-100471420","NCT05418647","Effect of Low Versus High Dialysate Sodium Concentration During Hemodialysis on Dialysis Recovery Time","Effect of Low Versus High Dialysate Sodium Concentration During Hemodialysis on Dialysis Recovery Time: A Prospective Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients with end-stage renal disease who have been prescribed long term hemodialysis and undergo four-hour HD treatments three times a week for more than 90 days.\n* Patient must be at least 18 years old. They must be able to read and write, as well as be in complete mental health.\n\nExclusion Criteria:\n\n* Inability to complete the surveys due to reading or hearing difficulties, actual instability of clinical condition that necessitate hospitalization, dementia, active malignancy or liver failure.",{"count":236,"type":20},40,[23],"This research aims to assess the effect of low versus high dialysate sodium concentration during hemodialysis on dialysis recovery time",[27],[241],"hemodialysis, recovery time, dialysate Na","2025-02-10",{"date":244,"type":34},"2025-02-11",{"date":246,"type":20},"2025-04-15",{"date":248,"type":20},"2025-08-15",{"name":250,"class":41},"Alexandria University",2,{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":21,"phases":261,"briefSummary":262,"conditions":263,"keywords":264,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":100},"100527909","ultrafiltration-rate-induced-cardiac-strain-ulrica---study-100527909","NCT06153888","ULtrafiltration-Rate Induced CArdiac Strain (ULRICA) - Study","The Effect of Hemodialysis on proBNP","ULRICA","Inclusion Criteria:\n\n* Adult HD patients with an intra-dialytic weight gain (IDWG) ≥2.5% of target weight over the long interval (3 days) prior to inclusion.\n* Patients need to be able to understand the study information\n* Patients need to be able to give consent.\n\nExclusion Criteria:\n\n* Active systemic inflammatory state such as extensive malignancy or acute septic infection.\n* Uncontrolled hyperphosphatemia decided by the local routine of the physician (due to somewhat decreased efficacy of the low flux filter to eliminate phosphate)",{"count":236,"type":20},[23],"Patients performing chronic hemodialysis (HD) retain more or less water between dialyses. The water is removed by ultrafiltration and usually during the cleansing of waste products - the HD. The length of HD is usually the same as the time of fluid removal while sometimes this may differ. There is no clear guideline. In previous research the investigator noted that the heart releases more NT-pro-BNP during HD in numerous of the patients.\n\nThe present study aims to clarify if the speed of fluid removal during HD is a factor that may alter the release of cardiac markers during HD. If so the recommendations for the prescription of HD can be updated.",[174,27],[265],"dialysis prescription","2024-12-10",{"date":268,"type":34},"2024-12-16",{"date":270,"type":34},"2023-03-20",{"date":272,"type":20},"2026-04-30",{"name":274,"class":41},"Umeå University",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":214,"sex":16,"minAge":283,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":21,"phases":287,"briefSummary":288,"conditions":289,"keywords":291,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":251},"100543779","plasma-biomarkers-of-muscle-metabolism-during-exercise-to-the-assessment-of-insulin-resistance-in-ckd-dialysis-patients-100543779","NCT06360302","Plasma Biomarkers of Muscle Metabolism During Exercise to the Assessment of Insulin Resistance in CKD Dialysis Patients","Contribution of Plasma Assays of Biomarkers of Muscle Metabolism During Exercise to the Assessment of Insulin Resistance in Chronic Renal Failure Patients Undergoing Hemodialysis.","KREBSome-IRC","Inclusion Criteria:\n\nGroup 1: Healthy subjects:\n\n* Postmenopausal women aged 40 to 75 or men aged 40 to 75\n* No chronic disease or treatment\n* BMI \\\u003C30 kg\u002Fm², or\n* Fasting blood glucose \\\u003C 1.10 g\u002FdL\n\nGroup 2: metabolic syndrome patients\n\n* Postmenopausal women aged 40 to 75 or men aged 40 to 75\n* Metabolic syndrome as defined by the International Diabetes Federation (IDF 2006)5\n* BMI \\\u003C30 kg\u002Fm² and waist circumference \\>80 cm for women and \\>94 cm for men\n* Insulin resistance defined by HOMA-IR\\>2.4\n\nGroup 3: CKD dialysis patients\n\n* Non-diabetics\n* Postmenopausal women aged 40 to 75 and men aged 40 to 75\n* BMI \\\u003C30 kg\u002Fm².\n* Chronic kidney disease patients on dialysis - stable on HD for more than 3 months\n\nPatients and healthy subjects will be matched on age (+\u002F-3 years) and sex\n\nExclusion Criteria:\n\n* Non-stabilized pathology incompatible with physical exercise\n* Ongoing exercise retraining program\n* Nutritional supplementation in the 4 weeks preceding the study (antioxidants, vitamins, etc.)\n* Treatment influencing mitochondrial function (metformin, statin, etc.)\n* Failure to obtain written informed consent after a period of reflection\n* Subject not affiliated to a social security scheme, or not benefiting from such a scheme.\n* Person protected by law (under guardianship or curatorship)\n* Patient deprived of liberty\n* Diabetic patient\n* Family dyslipidemia\n* Participants who have reached the maximum amount of compensation for their participation in research projects\n* Person under psychiatric care\n* Person participating in another research project with an exclusion period still in progress.\n* Mentally handicapped, dementia, illiterate, language barrier with inability to understand study purpose and methodology","40 Years","75 Years",{"count":286,"type":20},42,[23],"This prospective, multicenter, cross-sectional, repeated-measures comparative study compared functional and biochemical response profiles to exercise between 2 groups of chronically ill patients (chronic renal failure dialysis patients and patients with metabolic syndrome) and a group of healthy subjects.\n\nThe hypothesis is that the addition of plasma metabolic intermediates associated with energy disorders linked to insulin resistance, will improve the sensitivity of the assessment of muscle oxidative metabolism abnormalities, as reported in exercise intolerant subjects.\n\nIn this way, the metabolomics approach during exercise would provide a biological and functional \"signature\" of insulin resistance of muscular origin, discriminating between insulin-resistant patients, healthy control subjects and dialysis patients, with an exercise metabolic profile approaching that observed in insulin-resistant patients. A better understanding of metabolic abnormalities could guide muscle rehabilitation.\n\nParticipants will be asked to perform an exercise test, with several blood samples taken at different exercise intensities.\n\nResearchers will compare the metabolic profile of three groups: patients with chronic kidney disease, patients with metabolic syndrome and healthy subjects:\n\n* V'O2-adjusted lactate at rest and during exercise\n* The combination of exercise energy metabolism intermediates reflecting insulin resistance among Krebs cycle cofactors\u002Fsubstrates, ß-oxidation cofactors\u002Fsubstrates, amino acids",[290,27],"Metabolic Syndrome",[292,293,294],"exercise test","Citric Acid Cycle","metabolomic","2024-11-22",{"date":297,"type":34},"2024-11-26",{"date":299,"type":34},"2024-11-18",{"date":301,"type":20},"2026-11-18",{"name":303,"class":41},"University Hospital, Montpellier",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":21,"phases":313,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":100},"100558389","comparison-of-three-types-of-distal-arteriovenous-fistulas-sbavf-rcavf-and-rcavf-with-venous-branch-patch-100558389","NCT06550479","Comparison of Three Types of Distal Arteriovenous Fistulas: SBAVF, RCAVF, and RCAVF With Venous Branch Patch.","Comparison of Tree Types of Distal Arteriovenous Fistulas: Snuffbox Fistula (SBAVF), Radiocephalic Fistula (RCAVF) and RCAVF With Venous Branch Patch.","Inclusion Criteria:\n\n* Aged \\>18 years\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C20 mL\u002Fmin\u002F1.73 m2\n\nExclusion Criteria:\n\n* Heart failure of New York Heart Association functional class III or IV,\n* Episode of cardio- or cerebrovascular event or receiving intervention therapy within 3 months prior to screening.\n* The patient had the primary anastomosis in the past on ipsilateral extremity",{"count":312,"type":20},180,[23],"This study aims to determine which type of distal arteriovenous fistula (SBAVF, RCAVF, and RCAVF with venous branch patch) is most clinically favorable.\n\nThe recommendations and scientific evidence do not suggest which option should be chosen initially.\n\nThe investigators expect that results will show which type of the anastomosis should be preferred.",[27,113],"2024-08-08",{"date":318,"type":34},"2024-08-13",{"date":320,"type":34},"2024-01-01",{"date":322,"type":20},"2030-07-31",{"name":324,"class":41},"Wroclaw Medical University",{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":214,"sex":16,"minAge":332,"maxAge":284,"enrollmentInfo":333,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":100},"100513488","sodium-accumulation-study-in-haemodialysis-brain-study-100513488","NCT05966116","Sodium Accumulation Study in Haemodialysis: Brain Study","SASH-B","Inclusion Criteria:\n\n* Age 50-75 years inclusive\n* Male and female patients with CKD stage 5 receiving chronic haemodialysis\n* Patient has been dialysis dependent for at least 3 months\n* Must be able to follow simple instruction in English (on safety ground for MRI scans) and be able to understand the nature and requirements of the study\n\nExclusion Criteria:\n\n* Active infection or malignancy\n* Amputee\n* Pregnancy\n* Contraindication to MRI scanning including claustrophobia, pacemaker, metallic implants etc\n* Unable or unwilling to provide informed consent\n* Medical conditions or overall physical frailty precludes scan session in opinion of investigator\n* Any condition which could interfere with the patient's ability to comply with the study","50 Years",{"count":334,"type":20},10,"The aim of the research study is to look at a new type of MRI scanning that can measure the amount of sodium in different parts of the body. Sodium (or 'salt') levels are very important in maintaining health, and high levels lead to high blood pressure. This is very important to patients with kidney disease, as the kidney is the main organ that regulates the amount of sodium in the body. It is possible to measure blood sodium levels, but this does not tell us how much sodium is present in other areas of the body. Previously, it has not been possible measure this. Sodium MRI (Na-MRI) is a new type of MRI scanning that can directly measure sodium in other parts of body such as skin, muscles, kidneys, and brain. The investigators believe that this will help to guide treatment in patients with kidney disease who are on haemodialysis, research studies are needed to prove the benefits.",[27],"2024-08-07",{"date":339,"type":34},"2024-08-09",{"date":341,"type":34},"2024-07-18",{"date":343,"type":20},"2025-02",{"name":345,"class":41},"University Hospitals of Derby and Burton NHS Foundation Trust",{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":214,"sex":16,"minAge":51,"maxAge":354,"enrollmentInfo":355,"targetDuration":4,"studyType":21,"phases":356,"briefSummary":357,"conditions":358,"keywords":360,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":100},"100506460","the-safety-of-nafamostat-mesylate-for-patients-with-high-risk-bleeding-undergoing-hemodialysis-a-pilot-study-100506460","NCT05874674","The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study","The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Diathesis Undergoing Hemodialysis: A Pilot Study","Nafamostat","Inclusion Criteria:\n\n* platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month\n\nExclusion Criteria:\n\n* cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)","99 Years",{"count":53,"type":20},[23],"Comparison nafamostat and low molecular weight heparin among dialysis patients",[27,359],"Bleeding",[361,362,363,364],"dialysis","bleeding","nafamostat","heaprin","2024-07-28",{"date":367,"type":34},"2024-07-30",{"date":369,"type":34},"2023-12-01",{"date":371,"type":20},"2026-12-31",{"name":373,"class":41},"Wonju Severance Christian Hospital",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":214,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":382,"conditions":383,"keywords":386,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":100},"100427640","cardiac-tissue-sodium-assessment-in-ckd-patients-using-sodium-mri-100427640","NCT04848636","Cardiac Tissue Sodium Assessment in CKD Patients Using Sodium MRI","Sodium Assessment of the Cardiac Tissue in Chronic Kidney Disease Patients Using Sodium Magnetic Resonance Imaging","Inclusion Criteria:\n\n* Age greater than or equal to 18 years\n* For patients on maintenance hemodialysis: more than 3 months duration of therapy\n* For patients with CKD: evidence of kidney disease persisting \\> 3 months and no indications to start dialysis\n* For healthy controls: lack of kidney disease, cardiovascular disease, diabetes, liver cirrhosis and peripheral edema\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding or intending pregnancy\n* Contraindication to MRI scan\n\n  * Inability to tolerate MRI due to patient size and\u002For known history of claustrophobia.\n  * Mechanically implanted, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, tattoos, shunt, surgical staples (including clips or metallic sutures and\u002For ear implants.)",{"count":193,"type":20},"Chronic kidney disease (CKD) is prevalent worldwide and affects around 10% of people living in developed health economies. As the kidney loses its function in patients with CKD, the kidneys are unable to filter toxins out of the blood as efficiently as those of healthy individuals. Arguably, sodium (salt) is the most relevant toxin in CKD and can build up in the kidneys of patients with CKD. Salt build-up has also been found to occur in the heart muscle tissue and could drive the development of scarring of the heart muscle tissue which contributes to heart failure.\n\nUsing sodium magnetic resonance imaging (MRI), we would like to measure the levels of salt in the heart muscle tissue. We will examine whether the heart muscle tissue has high salt levels, and if so, whether this relates to any heart defects. A conventional proton MRI will be done to measure heart function. The MRI images of healthy volunteers, CKD patients, and those on hemodialysis will be analyzed for levels of salt and the findings will then be compared to the cardiac biomarkers (proteins or enzymes that are released into the blood when the heart is damaged or stressed) and fibrosis (scarring) measured from each patient's proton MRI images to establish a possible correlation. This research has the potential to precede additional studies that may investigate the effect of diuretics (a drug that increases the production of urine) on the heart muscle tissue of CKD patients.\n\nUsing sodium magnetic resonance imaging (MRI), it is possible to measure the sodium content in the cardiac tissue of patients with kidney disease. In this research study, it will be investigated whether the elevated levels of sodium in patients with kidney disease is also present in their hearts, and if so, whether this relates to cardiac abnormalities. Cardiac sodium MRI images of healthy volunteers, hemodialysis patients, and CKD patients will be analyzed for sodium content. This sodium information will then be compared to the biomarkers of cardiac function and fibrosis measured from each patient's proton MRI images in order to establish a possible correlation. This research has the potential to precede additional studies that may investigate the effect of diuretics on the cardiac tissue of kidney disease patients.",[384,27,385],"Chronic Kidney Diseases","Sodium Retention",[387,388,389],"Sodium MRI","Chronic Kidney Disease","Hemodialysis","2024-07-22",{"date":392,"type":34},"2024-07-24",{"date":394,"type":34},"2022-07-10",{"date":396,"type":20},"2025-12-31",{"name":398,"class":41},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":11,"sex":16,"minAge":332,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":21,"phases":408,"briefSummary":409,"conditions":410,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":100},"100435781","structured-program-of-exercise-for-recipients-of-kidney-transplantation-100435781","NCT04954690","Structured Program of Exercise for Recipients of Kidney Transplantation","SPaRKT","Inclusion Criteria:\n\n* On hemodialysis or peritoneal dialysis\n* Age ≥ 50 years\n* SPPB score ≤ 10\n* Telephone access\n* Internet access\n* Having a living donor kidney\n\nExclusion Criteria:\n\n* Already in an exercise program\n* Non-English speakers",{"count":407,"type":20},136,[23],"Older patients with end- stage kidney disease (ESKD) are at very high risk for functional impairment. Kidney transplantation (KT) has the potential to ameliorate the detrimental effects of ESKD on physical activity and functional status. However, KT alone may not meet the full extent of this potential, particularly for older or more impaired adults. In fact, activity declines immediately post-KT and fails to return to expected levels even 5 years post-KT. Older patients waitlisted for KT (most of whom are on dialysis) are therefore reliant on their pre-KT levels of exercise, which are also predictive of post-KT mortality.\n\n\"Prehabilitation\" has been used in other surgical populations to minimize functional loss, and a structured exercise program may be beneficial in the pre- KT setting. However, few waitlisted patients are able to participate in typical exercise interventions due to barriers such as severe fatigue. Older patients have additional barriers such as further mobility impairment and requiring substantial caregiver support. Therefore for older living donor kidney transplant candidates, it is necessary to address issues such as specifics of coaching, timing, and importantly, incorporate caregiver participation.\n\nThe overall objective of this proposal is to adapt a previously developed 8- week, home- based, structured exercise program among older (≥50 years) dialysis patients awaiting living donor KT, with a focus on caregiver involvement. The investigators will trial the exercise program as compared to usual care. The investigators will then pilot the refined intervention in a total of 72 patient-caregiver dyads, 48 of whom will undergo the proposed intervention (24 with caregiver participation, 24 without). The primary outcomes for the pilot will be change in physical performance and activity from baseline to after the intervention, along with measurements of exploratory quality of life outcomes. In addition, the investigators will measure these same outcomes at 3- months post KT to evaluate for a durable effect of the intervention. An additional post-transplantation outcome of interest will be number of days hospitalized within 3 months of transplantation.",[411,27,412,413],"Kidney Transplant; Complications","Physical Disability","Frailty Syndrome","2023-10-12",{"date":416,"type":34},"2023-10-16",{"date":418,"type":34},"2022-11-22",{"date":420,"type":20},"2029-07",{"name":422,"class":41},"University of California, San Francisco",{"id":424,"slug":425,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":100},"100469790","research-on-optimal-diagnosis-and-treatment-of-cardiorenal-syndrome-100469790","NCT05397392","Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome","ODT-CRS","Inclusion Criteria:\n\nPatients meet the diagnosis of various types of cardiorenal syndrome according to the classification standards of various types formulated by KDIGO and ADQI expert consensus. Different syndromes were identified and classified into five subtypes. Acute CRS (type 1): acute worsening of heart function (AHF-ACS) leading to kidney injury and\u002For dysfunction. Chronic cardio-renal syndrome (type 2): chronic abnormalities in heart function (CHF-CHD) leading to kidney injury and\u002For dysfunction. Acute reno-cardiac syndrome (type 3): acute worsening of kidney function (AKI) leading to heart injury and\u002For dysfunction. Chronic reno-cardiac syndrome (type 4): chronic kidney disease leading to heart injury, disease, and\u002For dysfunction. Secondary CRS (type 5): systemic conditions leading to simultaneous injury and\u002For dysfunction of heart and kidney.\n\nExclusion Criteria:\n\nPregnant or breastfeeding women; Female patients with recent birth plans; Patients who cannot follow up on medications.",{"count":431,"type":20},1200,"To estimate the characteristics, pathogenesis, risk factors and intervention measures for different stages of heart and kidney diseases, and to optimize the curative effects of different treatment schemes",[434,198,435,436,27,437],"Heart Failure","Kidney Injury","Heart Valve Diseases","Coronary Heart Disease","2022-05-30",{"date":440,"type":34},"2022-06-02",{"date":442,"type":34},"2016-01",{"date":444,"type":20},"2027-12",{"name":446,"class":41},"Nanjing First Hospital, Nanjing Medical University"]